Embark Health licence approvals bode well for MMJ Group
MMJ Group Holdings Limited (ASX:MMJ;OTC:MMJJF), an Australian-listed company that specialises in managing a portfolio of investments along the cannabis value-chain, has provided an update on the operations of MMJ’s largest investee, privately-held Embark Health Inc.
Embark Health’s Delta, BC facility has now received all occupancy and business licences required from the city of Delta, BC, and will commence the extraction of cannabis in April 2020.
This step was foreshadowed in an MMJ announcement on 13 February 2020 following the receipt of the company’s Health Canada licence necessary to operate the facility.
Embark Health is an emerging leader in cannabis extraction, with a focus on realising the full potential of the cannabis plant through scientific approaches to extraction and the production of quality products to enhance everyday life.
It is Embark's mandate to pursue the best production processes throughout product innovation and development, manufacturing and ''take to market'' lifecycles, resulting in unparalleled commercial and consumer extraction products.
Largest cannabis extraction business in Canada
Embark Health is seeking to create the largest cannabis (THC and CBD) extraction business in Canada with facilities in British Columbia and Ontario.
The group will begin production of cannabis extracts at its Delta facility immediately and has entered into several letters of intent to secure 300,000 kilograms of biomass from highly-credentialed suppliers as feedstock for the next 2 years.
Initially, Embark intends to produce Bubble Hash, Dry Sift Kief and Rosin for commercial sale, in addition to providing tolling services to a wide range of customers.
Other extraction techniques will be added as more rooms in the facility are licensed.
MMJ’s management highlighted that the investment in Embark Health demonstrates its capacity to originate early-stage unlisted investments in the cannabis sector with the prospect of realising potential gains on listing the public markets.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.